Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALPL | P05186 | 4/20 | 0.54 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10637058 | 0.96 | ALPL (0.50) | MEN1KMT2AALPLARALDH1A1 | |
| SCHEMBL8557706 | 0.89 | MEN1 (0.54) | MEN1KMT2AALPLARALDH1A1 | |
| SCHEMBL8555373 | 0.80 | ALPL (0.46) | MEN1KMT2AALPLARALDH1A1 | |
| SCHEMBL8733851 | 0.78 | ALDH1A1 (0.50) | MEN1KMT2AALPLARALDH1A1 | |
| SCHEMBL5322518 | 0.76 | ALPL (0.44) | MEN1KMT2AALPLARALDH1A1 | |
| SCHEMBL893875 | 0.74 | MEN1 (0.44) | MEN1KMT2AALPLARALDH1A1 | |
| SCHEMBL824432 | 0.73 | ALDH1A1 (0.62) | MEN1KMT2AALDH1A1HTTKDM4E | |
| SCHEMBL29714525 | 0.72 | POLB (0.59) | MEN1KMT2AALPLALDH1A1HTT | |
| SCHEMBL28663483 | 0.72 | POLB (0.59) | MEN1KMT2AALPLALDH1A1HTT | |
| SCHEMBL12960613 | 0.72 | MEN1 (0.35) | MEN1KMT2AALDH1A1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230403927-A1 | AROMATIC COMPOUNDS | UDC IRELAND LTD (IE) | 2023-12-14 | — | — | US | disclosed |
| US-20230403927-A1 | AROMATIC COMPOUNDS | UDC IRELAND LTD (IE) | 2023-12-14 | — | — | US | disclosed |
| US-11800787-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2023-10-24 | — | — | US | disclosed |
| US-11800787-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2023-10-24 | — | — | US | disclosed |
| EP-3160976-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-20170141329-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-05-18 | — | — | US | disclosed |
| US-20170141329-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-05-18 | — | — | US | disclosed |
| WO-2016000803-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | WO | disclosed |
| US-6013797-A | CURING AGENT WHICH CROSSLINKS RESINS BY DECYCLIZATION WITHOUT RELEASING VOLATILE ORGANIC COMPOUNDS; FORMALDEHYDE-FREE | CYTEC TECHNOLOGY CORP. (US) | 2000-01-11 | — | — | US | disclosed |
| EP-0885214-A1 | CYCLIC IMIDO-1,3,5-TRIAZINE CROSSLINKING AGENTS | Cytec Technology Corp. (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5807929-A | Cyclic imido-1,3,5-triazine crosslinking agents | CYTEC TECHNOLOGY CORP. (US) | 1998-09-15 | — | — | US | disclosed |
| WO-1997031914-A1 | CYCLIC IMIDO-1,3,5-TRIAZINE CROSSLINKING AGENTS | CYTEC TECHNOLOGY CORP. (US) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230403927-A1 | AROMATIC COMPOUNDS | TYR, CTCF, MITF | MEN1 2141/4885KMT2A 1055/4885ALPL 2580/4885 |
| US-20170141329-A1 | METAL COMPLEXES | AP1M1, SOD1, AP3M1 | MEN1 766/4885KMT2A 2648/4885ALPL 2574/4885 |
| US-11800787-B2 | Metal complexes | AP1M1, SOD1, AP3M1 | MEN1 766/4885KMT2A 2648/4885ALPL 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.